Logotipo del repositorio
Logotipo del repositorio
 

Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorDaza Arnedo, Rodrigo
dc.contributor.authorSánchez Polo, Vicente
dc.contributor.authorBenavides Garcia , Jenniffer
dc.contributor.authorGutiérrez, Juan Felipe
dc.contributor.authorRamos Clason, Enrique
dc.contributor.authorDomínguez, Daniel
dc.contributor.authorMera Rebutti, Giovany
dc.contributor.authorMadrid Mancia, Carlos
dc.contributor.authorTabora López, Rene
dc.contributor.authorRocha Meza, Manuel
dc.contributor.authorTabora López, Dany
dc.contributor.authorMuñoz Zambrano, James J
dc.contributor.authorLorca Herrera, Eduardo
dc.contributor.authorDina-Batlle, Eliana
dc.contributor.authorCieza Terrones, Michael
dc.contributor.authorProença de Moraes, Thyago
dc.contributor.authorRodriguez Yánez , Tomas
dc.contributor.authorOsorio, Washington
dc.contributor.authorArellano Cabeza, Alyi
dc.contributor.authorRico-Fontalvo, Jorge
dc.date.accessioned2026-03-16T22:03:36Z
dc.date.available2026-03-16T22:03:36Z
dc.date.issued2026
dc.description.abstractBACKGROUND Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) face high renal and cardiovascular risks. Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, has demonstrated efficacy in reducing these risks in clinical trials. However, its real-world safety and effectiveness remain underexplored in local settings. AIM To evaluate the real-world safety and effectiveness of finerenone in patients with T2DM and CKD across seven Latin American countries. METHODS We conducted an observational, multicenter, retrospective cohort study based on real-world data in 347 patients with T2DM and CKD [urinary albumin-creatinine ratio (UACR) > 30 mg/g]. Patients received finerenone (10 mg or 20 mg daily), and clinical and laboratory parameters were evaluated at baseline and after six months of treatment. RESULTS At baseline, median values (interquartile range) were: Glycated hemoglobin A1c 7.6% (6.8%-8.1%); estimated glomerular filtration rate 39.0 mL/minute/1.73 m2 (30.0-50.0); UACR 345 mg/g (189-760); systolic blood pressure 143 mmHg (130-160); diastolic blood pressure 79 mmHg (70-82); and serum potassium 4.4 mmol/L (4.1-4.7). After six months, significant reductions were observed: Glycated hemoglobin A1c to 7.0% (6.5%-7.9%); UACR to 81 mg/g (28-167); systolic blood pressure to 130 mmHg (120-140); and diastolic blood pressure to 73 mmHg (70-80). Serum potassium increased to 4.7 mmol/L (4.3-5.0), while estimated glomerular filtration rate remained stable at 41.6 mL/minute/1.73 m2 (27.0-52.0). CONCLUSION In our cohort of patients with CKD associated with T2DM, finerenone proved to be an effective short-term therapy for reducing albuminuria, demonstrating very good tolerance and a low risk of hyperkalemiaeng
dc.format.mimetypepdf
dc.identifier.citationArnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico- Fontalvo J. Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. World J Nephrol 2026; 15(1): 115933
dc.identifier.doihttps://dx.doi.org/10.5527/wjn.v15.i1.115933
dc.identifier.issn22206124 (Electrónico)
dc.identifier.urihttps://hdl.handle.net/20.500.12442/17409
dc.identifier.urlhttps://www.wjgnet.com/2220-6124/full/v15/i1/115933.htm?appgw_azwaf_jsc=d_ZPllLew6iswgEJrHn3QDlvydllCYeVBgwNquhds_z31GqIgD_tew30EM_0yL6aZSNLN87UrdqRVPf6Kfhc3oXteJQ_KRA69shwYIWVjiZy83wn0DrL0uRIrbe6jaDsSkDWWBdLFYg4CJ6msST3D0CQxe2RIXJv98xG0ml_CKX9D4cWNjAM--AKJuvgsfyNWkCaakbbPNFAd7iF-bka4Q1BLmBnROeJ0kws6x879z58kMt7x2muEw2vPN53CIeDPEgRdxG8W7O1s1Tt8KkOEzd75eR2xbfhfvH4NQYANi5IcBqgZgnFR3ISJar05gBl2ZyxWoBhqdKom9ePcGfljA
dc.language.isoeng
dc.publisherBaishideng Publishing Group Inc.eng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.sourceWorld Journal of Nephrologyeng
dc.sourceWorld J Nephroleng
dc.sourceVol.15   No.1   Año 2026 
dc.subjectFinerenoneeng
dc.subjectChronic kidney diseaseeng
dc.subjectType 2 diabeteseng
dc.subjectDiabetic nephropathyeng
dc.subjectAlbuminuriaeng
dc.subjectHyperkalemiaeng
dc.titleEfficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trialeng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científico
dcterms.referencesTuttle KR, Wong L, St Peter W, Roberts G, Rangaswami J, Mottl A, Kliger AS, Harris RC, Gee PO, Fowler K, Cherney D, Brosius FC 3rd, Argyropoulos C, Quaggin SE; Diabetic Kidney Disease Collaborative Task Force. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clin J Am Soc Nephrol 2022; 17: 1092-1103 [RCA] [PMID: 35649722 DOI: 10.2215/CJN.02980322eng
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024; 105: S117-S314 [RCA] [PMID: 38490803 DOI: 10.1016/j.kint.2023.10.018eng
dcterms.referencesAmerican Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47: S219-S230 [RCA] [PMID: 38078574 DOI: 10.2337/dc24-S011eng
dcterms.referencesRico Fontalvo J, Vázquez Jiménez LC, Rodríguez Yánez T, Daza Arnedo R, Raad Sarabia M, Montejo Hernández JD, Lopera Vargas M, Jiménez Quintero J. Enfermedad renal diabética: puesta al día. An Fac Cienc Méd (Asunción) 2022; 55: 86-98 [RCA] [DOI: 10.18004/anales/2022.055.03.86spa
dcterms.referencesDuru OK, Middleton T, Tewari MK, Norris K. The Landscape of Diabetic Kidney Disease in the United States. Curr Diab Rep 2018; 18: 14 [RCA] [PMID: 29457196 DOI: 10.1007/s11892-018-0980-xeng
dcterms.referencesPitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARODKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385: 2252-2263 [RCA] [PMID: 34449181 DOI: 10.1056/NEJMoa2110956eng
dcterms.referencesFilippatos G, Anker SD, Pitt B, McGuire DK, Rossing P, Ruilope LM, Butler J, Jankowska EA, Michos ED, Farmakis D, Farjat AE, Kolkhof P, Scalise A, Joseph A, Bakris GL, Agarwal R. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother 2022; 9: 85-93 [RCA] [PMID: 36251465 DOI: 10.1093/ehjcvp/pvac054eng
dcterms.referencesInker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS; Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med 2021; 385: 1737-1749 [RCA] [PMID: 34554658 DOI: 10.1056/NEJMoa2102953eng
dcterms.referencesBaran W, Krzemińska J, Szlagor M, Wronka M, Młynarska E, Franczyk B, Rysz J. Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease. Int J Mol Sci 2021; 22: 9995 [RCA] [PMID: 34576158 DOI: 10.3390/ijms22189995eng
dcterms.referencesBakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIODKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383: 2219-2229 [RCA] [PMID: 33264825 DOI: 10.1056/NEJMoa2025845eng
dcterms.referencesCastillo GA, Aroca G, Buelvas J, Buitrago AF, Carballo V, Cárdenas JM, Gómez EA, Fériz K, Lopera JM, Melgarejo E, Restrepo K, Montejo JD, Pinzón JB, Quintero A, Rico JE, Rosero R. Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2. Rev Colomb Cardiol 2020; 27: 3-22 [RCA] [DOI: 10.1016/j.rccar.2020.07.005spa
dcterms.referencesChaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab 2022; 24: 365-376 [RCA] [PMID: 34779091 DOI: 10.1111/dom.14601eng
dcterms.referencesKolkhof P, Bärfacker L. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 2017; 234: T125-T140 [RCA] [PMID: 28634268 DOI: 10.1530/JOE-16-0600eng
dcterms.referencesRico Fontalvo J, Montejo Hernández J, Vázquez Jiménez L, Rodríguez Yánez T, Daza Arnedo R, Cardona Blanco MX, López Lozano J, Plaza Rivero M. Bloqueo del eje renina angiontensina aldosterona (RAAS) en la enfermedad renal diabética. Más allá del control de la hipertensión arterial. An Fac Cienc Méd (Asunción) 2023; 56: 46-57 [DOI: 10.18004/anales/2023.056.01.46spa
dcterms.referencesNaaman SC, Bakris GL. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care 2023; 46: 1574-1586 [RCA] [PMID: 37625003 DOI: 10.2337/dci23-0030eng
dcterms.referencesRico-Fontalvo J, Daza-Arnedo R, Aguilar-Salcedo N, Alfaro M, Navas-Torrejano D, Cardona-Blanco M, Uparella-Gulfo I, Raad-Sarabia M, Abuabara-Franco E, Cabrales J. Nueva evidencia en el tratamiento de la enfermedad renal diabética: ¿qué aporta la finerenona? Rev Colomb Nefrol 2022; 9: e603 [RCA] [DOI: 10.22265/acnef.9.3.603spa
dcterms.referencesYama-Mosquera E, Montejo Hernández JD, Chacón Acevedo KR, Daza R, De la Espriella-Badel V, Machacon Miranda E, Henao CM, Guevara JG, Parra Serrano PA, Lopera Vargas JM, Pertuz A, López Garcés JG, Rozo Agudelo N, Cárdenas JG, López López E, Rico-Fontalvo J. Actualización de la guía colombiana de práctica clínica sobre enfermedad renal diabética. Rev Colomb Nefrol 2024; 11: e912 [DOI: 10.22265/acnef.11.3.912spa
dcterms.referencesRico Fontalvo JE. Enfermedad renal diabética: de cara a la prevención, diagnóstico e intervención temprana. Rev Colomb Nefrol 2020; 7: 15- 16 [RCA] [DOI: 10.22265/acnef.7.2.506spa
dcterms.referencesArellano AA, Castilla SM, Ortiz E, Lozano T. Perspectiva actual en manejo de Arritmias en Cardiomiopatía Chagásica. Rev Cienc Biomed 2022; 11: 211-222 [DOI: 10.32997/rcb-2022-4061spa
dcterms.referencesCurrie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, Boesby L, Edwards NC, Ferro CJ, Townend JN, van den Meiracker AH, Saklayen MG, Oveisi S, Jardine AG, Delles C, Preiss DJ, Mark PB. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol 2016; 17: 127 [RCA] [PMID: 27609359 DOI: 10.1186/s12882-016-0337-0eng
dcterms.referencesBarrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 2019; 96: 302-319 [RCA] [PMID: 31133455 DOI: 10.1016/j.kint.2019.02.030eng
dcterms.referencesMartinez Vargas V, Menon T, Castro M, Vijayaraghavan K. Evidence of clinical trials of cardiac outcomes on renal disease. In: Rao GHR, Das UN, editors. Cardiometabolic Diseases. Academic Press, 2025: 117-128 [DOI: 10.1016/B978-0-323-95469-3.00028-0eng
dcterms.referencesChallenges. Int J Mol Sci 2023; 24: 7719 [RCA] [PMID: 37175424 DOI: 10.3390/ijms24097719eng
dcterms.referencesSingh AK, Singh A, Singh R, Misra A. Finerenone in diabetic kidney disease: A systematic review and critical appraisal. Diabetes Metab Syndr 2022; 16: 102638 [RCA] [PMID: 36223666 DOI: 10.1016/j.dsx.2022.102638eng
dcterms.referencesHanouneh M, Le D, Jaar BG, Tamargo C, Cervantes CE. Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease. Diagnostics (Basel) 2024; 14: 1357 [RCA] [PMID: 39001247 DOI: 10.3390/diagnostics14131357eng
dcterms.referencesBakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015; 314: 884-894 [RCA] [PMID: 26325557 DOI: 10.1001/jama.2015.10081eng
dcterms.referencesDi Lullo L, Lavalle C, Scatena A, Mariani MV, Ronco C, Bellasi A. Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. J Clin Med 2023; 12: 3992 [RCA] [PMID: 37373685 DOI: 10.3390/jcm12123992eng
dcterms.referencesand FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484 [RCA] [PMID: 35023547 DOI: 10.1093/eurheartj/ehab777eng
dcterms.referencesPitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392 [RCA] [PMID: 24716680 DOI: 10.1056/NEJMoa1313731eng
dcterms.referencesZannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21 [RCA] [PMID: 21073363 DOI: 10.1056/NEJMoa1009492eng
dcterms.referencesFolkerts K, Millier A, Smela B, Olewinska E, Schmedt N, Mernagh P, Kovesdy CP. Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. J Nephrol 2023; 36: 1135-1167 [RCA] [PMID: 36422853 DOI: 10.1007/s40620-022-01492-weng
dcterms.referencesViswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med 2024; 30: 3758-3764 [RCA] [PMID: 39218030 DOI: 10.1038/s41591-024-03264-4eng
dcterms.referencesBello AK, Okpechi IG, Levin A, Johnson DW. Variations in kidney care management and access: regional assessments of the 2023 International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA). Kidney Int Suppl (2011) 2024; 13: 1-5 [RCA] [PMID: 38619132 DOI: 10.1016/j.kisu.2023.12.001eng
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
PDF.pdf
Tamaño:
2.09 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca